PDS Biotechnology reports Q1 EPS (30c), consensus (37c)
PremiumThe FlyPDS Biotechnology reports Q1 EPS (30c), consensus (37c)
2M ago
PDSB Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
PDSB Upcoming Earnings Report: What to Expect?
2M ago
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PremiumPress Releases
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
3M ago
PDS Biotechnology Welcomes Stephan Toutain as New COO
PremiumCompany AnnouncementsPDS Biotechnology Welcomes Stephan Toutain as New COO
3M ago
PDS Biotechnology to host KOL event on Phase 2 VERSATILE-002 trial
PremiumThe Fly
PDS Biotechnology to host KOL event on Phase 2 VERSATILE-002 trial
3M ago
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
PremiumPress Releases
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
3M ago
PDS Biotechnology reports 2023 EPS ($1.39), consensus ($1.46)
PremiumThe FlyPDS Biotechnology reports 2023 EPS ($1.39), consensus ($1.46)
4M ago
PDS Biotechnology to prioritize triple combination in place of VERSATILE-003
PremiumThe Fly
PDS Biotechnology to prioritize triple combination in place of VERSATILE-003
4M ago
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100